D.E. Shaw & Co’s Psyence Biomedical Warrant PBMWW Stock Holding History

D.E. Shaw & Co’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.68K	Hold	175,352	–	–	﹤0.01%	4811
2026 Q1	$3.17K	Hold	175,352	–	–	﹤0.01%	4455
2025 Q4	$3.45K	Hold	175,352	–	–	﹤0.01%	4534
2025 Q3	$4.38K	Hold	175,352	–	–	﹤0.01%	4487
2025 Q2	$3.54K	Hold	175,352	–	–	﹤0.01%	4285
2025 Q1	$2.96K	Hold	175,352	–	–	﹤0.01%	4180
2024 Q4	$2.16K	Hold	175,352	–	–	﹤0.01%	4331
2024 Q3	$2.23K	Hold	175,352	–	–	﹤0.01%	4461
2024 Q2	$1.86K	Hold	175,352	–	–	﹤0.01%	4406
2024 Q1	$12.6K	Buy	+175,352	New	+$10.9K	﹤0.01%	4152

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

D.E. Shaw & Co's PBMWW Position: Q2 2026 in Review

D.E. Shaw & Co held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 175,352 shares worth $3.68K. The position accounts for ﹤0.01% of the portfolio, ranked #4811.

D.E. Shaw & Co first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.6K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

D.E. Shaw & Co held 175,352 shares of Psyence Biomedical Warrant worth $3.68K as of Q2 2026.
D.E. Shaw & Co left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4811 holding.
D.E. Shaw & Co first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
D.E. Shaw & Co's Psyence Biomedical Warrant position peaked at $12.6K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.